Skip to content
2000
image of Hypothesis-Driven Insights and Clinical Trial Updates in Alzheimer’s Disease Pathogenesis

Abstract

Background

Alzheimer's disease (AD) is the primary cause of dementia and a significant threat to healthy aging. The prevalence of AD and other non-communicable diseases (NCDs) is significantly influenced by the progressive decline in physiological functions that is associated with aging.

Methods

This review summarizes the results of drug interventions for AD that have been conducted in the past five years, with a particular emphasis on Phase I, Phase III, and Phase IV clinical trials. Systematic investigations of clinical trial registries and databases were employed to identify clinical trials. A total of 106 Phase I, 52 Phase III, and 13 Phase IV trials were considered, excluding studies on devices, biologics, and diagnostic tests.

Results

this review summarizes a wide range of therapy approaches aimed at different facets of AD pathogenesis, including amyloid-beta aggregation, tau protein dysfunction, neuroinflammation, synapse loss, and metabolic dysregulation. AD’s complex nature highlights the need for multi-target treatment strategies, which may encompass combination therapies and innovative targets that show potential in addressing the complex pathogenesis of AD.

Discussion

Current clinical studies demonstrate a variety of therapies aimed at various pathogenic processes of AD. Progress in therapeutic discovery, including synthetic molecules and bioactive natural materials, suggests potential strategies for successful AD treatment. The efficacy of natural products as therapeutic agents is especially significant because of their multi-target effects.

Conclusion

Effective strategies to prevent the progression of AD require a thorough comprehension of its complex pathophysiology. Current clinical studies are essential for discovering viable chemicals and treatment strategies to combat this multifactorial neurodegenerative disorder, AD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273387383250924031644
2025-10-21
2025-11-25

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273387383250924031644
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Duong S. Patel T. Chang F. Dementia: What pharmacists need to know. Can Pharm J 2017 150 2 118 129 10.1177/1715163517690745 28405256
    [Google Scholar]
  2. Cipriani G. Danti S. Picchi L. Nuti A. Fiorino M.D. Daily functioning and dementia. Dement. Neuropsychol. 2020 14 2 93 102 10.1590/1980‑57642020dn14‑020001 32595877
    [Google Scholar]
  3. Moscoso A. Silva-Rodríguez J. Aldrey J.M. Cortés J. Fernández-Ferreiro A. Gómez-Lado N. Ruibal Á. Aguiar P. Prediction of Alzheimer’s disease dementia with MRI beyond the short-term: Implications for the design of predictive models. Neuroimage Clin. 2019 23 101837 10.1016/j.nicl.2019.101837 31078938
    [Google Scholar]
  4. Lee T. Lee H. Prediction of Alzheimer’s disease using blood gene expression data. Sci. Rep. 2020 10 1 3485 10.1038/s41598‑020‑60595‑1 32103140
    [Google Scholar]
  5. Dumurgier J. Sabia S. Life expectancy in dementia subtypes: Exploring a leading cause of mortality. Lancet Healthy Longev. 2021 2 8 e449 e450 10.1016/S2666‑7568(21)00166‑5 36097991
    [Google Scholar]
  6. Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med. Clin. North Am. 2019 103 2 263 293 10.1016/j.mcna.2018.10.009 30704681
    [Google Scholar]
  7. Iida M.A. Farrell K. Walker J.M. Richardson T.E. Marx G.A. Bryce C.H. Purohit D. Ayalon G. Beach T.G. Bigio E.H. Cortes E.P. Gearing M. Haroutunian V. McMillan C.T. Lee E.B. Dickson D.W. McKee A.C. Stein T.D. Trojanowski J.Q. Woltjer R.L. Kovacs G.G. Kofler J.K. Kaye J. White C.L. III Crary J.F. Predictors of cognitive impairment in primary age-related tauopathy: An autopsy study. Acta Neuropathol. Commun. 2021 9 1 134 10.1186/s40478‑021‑01233‑3 34353357
    [Google Scholar]
  8. Gouras G.K. Tampellini D. Takahashi R.H. Capetillo-Zarate E. Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol. 2010 119 5 523 541 10.1007/s00401‑010‑0679‑9 20354705
    [Google Scholar]
  9. Mendonça C.F. Kuras M. Nogueira F.C.S. Plá I. Hortobágyi T. Csiba L. Palkovits M. Renner É. Döme P. Marko-Varga G. Domont G.B. Rezeli M. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer’s disease. Neurobiol. Dis. 2019 130 104509 10.1016/j.nbd.2019.104509 31207390
    [Google Scholar]
  10. King A. Bodi I. Troakes C. The neuropathological diagnosis of Alzheimer’s disease—The challenges of pathological mimics and concomitant pathology. Brain Sci. 2020 10 8 479 10.3390/brainsci10080479 32722332
    [Google Scholar]
  11. Arora H. Ramesh M. Rajasekhar K. Govindaraju T. Molecular tools to detect alloforms of Aβ and Tau: Implications for multiplexing and multimodal diagnosis of Alzheimer’s disease. Bull. Chem. Soc. Jpn. 2020 93 4 507 546 10.1246/bcsj.20190356
    [Google Scholar]
  12. Chen Y. Wang J. Cui C. Su Y. Jing D. Wu L. Liang P. Liang Z. Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer’s disease: A PET/MRI study. Aging 2021 13 5 7228 7246 10.18632/aging.202580 33640881
    [Google Scholar]
  13. Weston P.S.J. Simpson I.J.A. Ryan N.S. Ourselin S. Fox N.C. Diffusion imaging changes in grey matter in Alzheimer’s disease: A potential marker of early neurodegeneration. Alzheimers Res. Ther. 2015 7 1 47 10.1186/s13195‑015‑0132‑3 26136857
    [Google Scholar]
  14. Qiu R. Ahn J.E. Alexander R. Brodney M.A. He P. Leurent C. Mancuso J. Margolin R.A. Tankisheva E. Chen D. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of PF-06751979, a potent and selective oral BACE1 inhibitor: Results from phase I studies in healthy adults and healthy older subjects. J. Alzheimers Dis. 2019 71 2 581 595 10.3233/JAD‑190228 31424395
    [Google Scholar]
  15. Gauthier S. Feldman H.H. Schneider L.S. Wilcock G.K. Frisoni G.B. Hardlund J.H. Moebius H.J. Bentham P. Kook K.A. Wischik D.J. Schelter B.O. Davis C.S. Staff R.T. Bracoud L. Shamsi K. Storey J.M.D. Harrington C.R. Wischik C.M. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016 388 10062 2873 2884 10.1016/S0140‑6736(16)31275‑2 27863809
    [Google Scholar]
  16. Salemme S. Ancidoni A. Locuratolo N. Piscopo P. Lacorte E. Canevelli M. Vanacore N. Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: Clinical and public health issues. Expert Rev. Neurother. 2023 23 12 1113 1129 10.1080/14737175.2023.2284305 37975226
    [Google Scholar]
  17. Agarwal A. Gupta V. Brahmbhatt P. Desai A. Vibhute P. Joseph-Mathurin N. Bathla G. Amyloid-related imaging abnormalities in Alzheimer disease treated with Anti–Amyloid-β therapy. Radiographics 2023 43 9 e230009 10.1148/rg.230009 37651273
    [Google Scholar]
  18. Pfundstein G. Nikonenko A.G. Sytnyk V. Amyloid precursor protein (APP) and amyloid β (Aβ) interact with cell adhesion molecules: Implications in Alzheimer’s disease and normal physiology. Front. Cell Dev. Biol. 2022 10 969547 10.3389/fcell.2022.969547 35959488
    [Google Scholar]
  19. Sepehri A. Lazaridis T. Putative structures of membrane-embedded amyloid β oligomers. ACS Chem. Neurosci. 2023 14 1 99 110 10.1021/acschemneuro.2c00535 36525690
    [Google Scholar]
  20. Tolar M. Hey J. Power A. Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression. Int. J. Mol. Sci. 2021 22 12 6355 10.3390/ijms22126355 34198582
    [Google Scholar]
  21. Li S. Selkoe D.J. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain. J. Neurochem. 2020 154 6 583 597 10.1111/jnc.15007 32180217
    [Google Scholar]
  22. Wang Y. Shi Z. Zhang Y. Yan J. Yu W. Chen L. Oligomer β-amyloid induces hyperactivation of Ras to impede NMDA receptor-dependent long-term potentiation in hippocampal CA1 of mice. Front. Pharmacol. 2020 11 595360 10.3389/fphar.2020.595360 33536910
    [Google Scholar]
  23. Rodriguez G.A. Tai L.M. LaDu M.J. Rebeck G.W. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J. Neuroinflammation 2014 11 1 111 10.1186/1742‑2094‑11‑111 24948358
    [Google Scholar]
  24. Basak J.M. Ferreiro A. Cohen L.S. Sheehan P.W. Nadarajah C.J. Kanan M.F. Sukhum K.V. Dantas G. Musiek E.S. Bacterial sepsis increases hippocampal fibrillar amyloid plaque load and neuroinflammation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 2021 152 105292 10.1016/j.nbd.2021.105292 33556539
    [Google Scholar]
  25. Sheng J. Bora S.H. Xu G. Borchelt D.R. Price D.L. Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice. Neurobiol. Dis. 2003 14 1 133 145 10.1016/S0969‑9961(03)00069‑X 13678674
    [Google Scholar]
  26. Wright A.L. Zinn R. Hohensinn B. Konen L.M. Beynon S.B. Tan R.P. Clark I.A. Abdipranoto A. Vissel B. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One 2013 8 4 e59586 10.1371/journal.pone.0059586 23560052
    [Google Scholar]
  27. Villemagne V.L. Burnham S. Bourgeat P. Brown B. Ellis K.A. Salvado O. Szoeke C. Macaulay S.L. Martins R. Maruff P. Ames D. Rowe C.C. Masters C.L. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2013 12 4 357 367 10.1016/S1474‑4422(13)70044‑9 23477989
    [Google Scholar]
  28. Zhu X. Lee H. Perry G. Smith M.A. Alzheimer disease, the two-hit hypothesis: An update. Biochim. Biophys. Acta Mol. Basis Dis. 2007 1772 4 494 502 10.1016/j.bbadis.2006.10.014
    [Google Scholar]
  29. Lloret A. Fuchsberger T. Giraldo E. Viña J. Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease. Free Radic. Biol. Med. 2015 83 186 191 10.1016/j.freeradbiomed.2015.02.028 25746773
    [Google Scholar]
  30. Rozemuller A. van Gool W. Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer’s disease: Therapeutic implications. Curr. Drug Targets CNS Neurol. Disord. 2005 4 3 223 233 10.2174/1568007054038229 15975026
    [Google Scholar]
  31. Barbier P. Zejneli O. Martinho M. Lasorsa A. Belle V. Smet-Nocca C. Tsvetkov P.O. Devred F. Landrieu I. Role of tau as a microtubule-associated protein: Structural and functional aspects. Front. Aging Neurosci. 2019 11 204 10.3389/fnagi.2019.00204 31447664
    [Google Scholar]
  32. Zhou Y. Shi J. Chu D. Hu W. Guan Z. Gong C.X. Iqbal K. Liu F. Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer’s disease. Front. Aging Neurosci. 2018 10 27 10.3389/fnagi.2018.00027 29472853
    [Google Scholar]
  33. Arriagada P.V. Growdon J.H. Hedley-Whyte E.T. Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992 42 3 631 639 10.1212/WNL.42.3.631 1549228
    [Google Scholar]
  34. Yasuno F. Minami H. Hattori H. Relationship between neuropsychiatric symptoms and Alzheimer’s disease pathology: An in vivo positron emission tomography study. Int. J. Geriatr. Psychiatry 2021 36 4 598 605 10.1002/gps.5459 33165946
    [Google Scholar]
  35. Wu M. Zhang M. Yin X. Chen K. Hu Z. Zhou Q. Cao X. Chen Z. Liu D. The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases. Transl. Neurodegener. 2021 10 1 45 10.1186/s40035‑021‑00270‑1 34753506
    [Google Scholar]
  36. Schoonhoven D.N. Coomans E.M. Millán A.P. van Nifterick A.M. Visser D. Ossenkoppele R. Tuncel H. van der Flier W.M. Golla S.S.V. Scheltens P. Hillebrand A. van Berckel B.N.M. Stam C.J. Gouw A.A. Tau protein spreads through functionally connected neurons in Alzheimer’s disease: A combined MEG/PET study. Brain 2023 146 10 4040 4054 10.1093/brain/awad189 37279597
    [Google Scholar]
  37. Akide Ndunge O.B. Shikani H.J. Dai M. Freeman B.D. Desruisseaux M.S. Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria. J. Neurochem. 2023 167 3 441 460 10.1111/jnc.15972 37814468
    [Google Scholar]
  38. Nathanson N.M. Muscarinic Acetylcholine Receptors. In: Reference Module in Biomedical Sciences. Elsevier 2018 10.1016/B978‑0‑12‑801238‑3.11143‑2
    [Google Scholar]
  39. Kucherenko D.Y. Kucherenko I.S. Soldatkin O.O. Topolnikova Y.V. Dzyadevych S.V. Soldatkin A.P. A highly selective amperometric biosensor array for the simultaneous determination of glutamate, glucose, choline, acetylcholine, lactate and pyruvate. Bioelectrochemistry 2019 128 100 108 10.1016/j.bioelechem.2019.03.010 30959397
    [Google Scholar]
  40. Ferreira-Vieira T.H. Guimaraes I.M. Silva F.R. Ribeiro F.M. Alzheimer’s disease: Targeting the cholinergic system. Curr. Neuropharmacol. 2016 14 1 101 115 10.2174/1570159X13666150716165726 26813123
    [Google Scholar]
  41. Leitz J. Kavalali E.T. Ca2+ dependence of synaptic vesicle endocytosis. Neuroscientist 2016 22 5 464 476 10.1177/1073858415588265 25998187
    [Google Scholar]
  42. Albanus L. Central and peripheral effects of anticholinergic compounds. Acta Pharmacol. Toxicol. 1970 28 4 305 326 10.1111/j.1600‑0773.1970.tb00557.x 5536020
    [Google Scholar]
  43. Pradhan S.N. Roth T. Comparative behavioral effects of several anticholinergic agents in rats. Psychopharmacology 1968 12 4 358 366 10.1007/BF00401415 5652217
    [Google Scholar]
  44. Davies P. Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976 308 8000 1403 10.1016/S0140‑6736(76)91936‑X 63862
    [Google Scholar]
  45. Rylett R.J. Ball M.J. Colhoun E.H. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer’s disease. Brain Res. 1983 289 1-2 169 175 10.1016/0006‑8993(83)90017‑3 6661641
    [Google Scholar]
  46. Nilsson L. Nordberg A. Hardy J. Wester P. Winblad B. Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level. J. Neural Transm. 1986 67 3-4 275 285 10.1007/BF01243353 3806081
    [Google Scholar]
  47. Whitehouse P.J. Martino A.M. Antuono P.G. Lowenstein P.R. Coyle J.T. Price D.L. Kellar K.J. Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res. 1986 371 1 146 151 10.1016/0006‑8993(86)90819‑X 3708340
    [Google Scholar]
  48. Almasieh M. MacIntyre J.N. Pouliot M. Casanova C. Vaucher E. Kelly M.E.M. Di Polo A. Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 2013 54 5 3171 3183 10.1167/iovs.12‑11481 23599333
    [Google Scholar]
  49. Katz N.K. Barohn R.J. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis. Neuropharmacology 2021 182 108303 10.1016/j.neuropharm.2020.108303 32918950
    [Google Scholar]
  50. Muramoto O. Sugishita M. Sugita H. Toyokura Y. Effect of physostigmine on constructional and memory tasks in Alzheimer’s disease. Arch. Neurol. 1979 36 8 501 503 10.1001/archneur.1979.00500440071014 508162
    [Google Scholar]
  51. Robertson D.A. The calabar bean as a new agent in ophthalmic medicine. Edinburgh Med. J. 1863 8 9 815 10.5962/bhl.title.103024
    [Google Scholar]
  52. Walker M.B. Case showing the effect of prostigmin on myasthenia gravis. SAGE Publications 1935 10.1177/003591573502800633
    [Google Scholar]
  53. Haake A. Nguyen K. Friedman L. Chakkamparambil B. Grossberg G.T. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin. Drug Saf. 2020 19 2 147 157 10.1080/14740338.2020.1721456 31976781
    [Google Scholar]
  54. Xiao S. Wang T. Ma X. Qin Y. Li X. Zhao Z. Liu X. Wang X. Xie H. Jiang Q. Sun L. Luo B. Shang L. Chen W. Bai Y. Tang M. He M. Wu L. Ma Q. Hou D. He J. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer’s disease: A Phase II multicenter randomised controlled trial. Age Ageing 2017 46 5 767 773 10.1093/ageing/afx045 28419192
    [Google Scholar]
  55. Popiolek M. Mandelblat-Cerf Y. Young D. Garst-Orozco J. Lotarski S.M. Stark E. Kramer M. Butler C.R. Kozak R. In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: Implications for treatment of Alzheimer’s disease and Schizophrenic patients. ACS Chem. Neurosci. 2019 10 3 1091 1098 10.1021/acschemneuro.8b00496 30335349
    [Google Scholar]
  56. Mistry S.N. Jörg M. Lim H. Vinh N.B. Sexton P.M. Capuano B. Christopoulos A. Lane J.R. Scammells P.J. 4-Phenylpyridin-2-one derivatives: A novel class of positive allosteric modulator of the M1 muscarinic acetylcholine receptor. J. Med. Chem. 2016 59 1 388 409 10.1021/acs.jmedchem.5b01562 26624844
    [Google Scholar]
  57. Verma S. Kumar A. Tripathi T. Kumar A. Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer’s disease therapy. J. Pharm. Pharmacol. 2018 70 8 985 993 10.1111/jphp.12919 29663387
    [Google Scholar]
  58. Yeomans J.S. Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions. Handb Exp Pharmacol 2012 208 243 259 10.1007/978‑3‑642‑23274‑9_11 22222702
    [Google Scholar]
  59. Radu B.M. Osculati A.M.M. Suku E. Banciu A. Tsenov G. Merigo F. Di Chio M. Banciu D.D. Tognoli C. Kacer P. Giorgetti A. Radu M. Bertini G. Fabene P.F. All muscarinic acetylcholine receptors (M1-M5) are expressed in murine brain microvascular endothelium. Sci. Rep. 2017 7 1 5083 10.1038/s41598‑017‑05384‑z 28698560
    [Google Scholar]
  60. Saternos H.C. Almarghalani D.A. Gibson H.M. Meqdad M.A. Antypas R.B. Lingireddy A. AbouAlaiwi W.A. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol. Genomics 2018 50 1 1 9 10.1152/physiolgenomics.00062.2017 29093194
    [Google Scholar]
  61. Puri V. Wang X. Vardigan J.D. Kuduk S.D. Uslaner J.M. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer’s disease mouse model. Behav. Brain Res. 2015 287 96 99 10.1016/j.bbr.2015.03.029 25800972
    [Google Scholar]
  62. Lebois E.P. Schroeder J.P. Esparza T.J. Bridges T.M. Lindsley C.W. Conn P.J. Brody D.L. Daniels J.S. Levey A.I. Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer’s disease mouse model. ACS Chem. Neurosci. 2017 8 6 1177 1187 10.1021/acschemneuro.6b00278 28230352
    [Google Scholar]
  63. Hall H. Iulita M.F. Gubert P. Flores Aguilar L. Ducatenzeiler A. Fisher A. Cuello A.C. AF710B, an M1/sigma‐1 receptor agonist with long‐lasting disease‐modifying properties in a transgenic rat model of Alzheimer’s disease. Alzheimers Dement. 2018 14 6 811 823 10.1016/j.jalz.2017.11.009 29291374
    [Google Scholar]
  64. Phase 1 study of ANAVEX3-71. NCT04442945 2022 Available from: https://clinicaltrials.gov/
  65. ANAVEX2-73 for Treatment of Early Alzheimer's disease. NCT03790709 2022 Available from: https://clinicaltrials.gov/
  66. Yi J.H. Whitcomb D.J. Park S.J. Martinez-Perez C. Barbati S.A. Mitchell S.J. Cho K. M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer’s disease pathology. Brain Commun. 2020 2 2 fcaa058 10.1093/braincomms/fcaa058 32766549
    [Google Scholar]
  67. Berk C. Sabbagh M.N. Successes and failures for drugs in late-stage development for Alzheimer’s disease. Drugs Aging 2013 30 10 783 792 10.1007/s40266‑013‑0108‑6 23943247
    [Google Scholar]
  68. Dziewczapolski G. Glogowski C.M. Masliah E. Heinemann S.F. Deletion of the α 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J. Neurosci. 2009 29 27 8805 8815 10.1523/JNEUROSCI.6159‑08.2009 19587288
    [Google Scholar]
  69. Leszek J. Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: Role of brain innate immune system. CNS Neurol Disord Drug Targets 2016 15 3 329 336 10.2174/1871527315666160202125914 26831258
    [Google Scholar]
  70. Taipa R. Sousa A.L. Melo Pires M. Sousa N. Does the interplay between aging and neuroinflammation modulate Alzheimer’s disease clinical phenotypes? A clinico-pathological perspective. J. Alzheimers Dis. 2016 53 2 403 417 10.3233/JAD‑160121 27176075
    [Google Scholar]
  71. Wang X. Wang W. Li L. Perry G. Lee H. Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim. Biophys. Acta Mol. Basis Dis. 2014 1842 8 1240 1247 10.1016/j.bbadis.2013.10.015 24189435
    [Google Scholar]
  72. Umeno A. Biju V. Yoshida Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer’s disease, Parkinson’s disease, and diabetes. Free Radic. Res. 2017 51 4 413 427 10.1080/10715762.2017.1315114 28372523
    [Google Scholar]
  73. Calvo-Rodriguez M. Kharitonova E.K. Snyder A.C. Hou S.S. Sanchez-Mico M.V. Das S. Fan Z. Shirani H. Nilsson K.P.R. Serrano-Pozo A. Bacskai B.J. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease. Mol. Neurodegener. 2024 19 1 6 10.1186/s13024‑024‑00702‑2 38238819
    [Google Scholar]
  74. Zhou F-T. Shuangrong C. Qu L. Reactive oxygen species mediate abnormal tau phosphorylation in a zinc-induced model. J. Neurol. Sci. 2015 32 1 115 121
    [Google Scholar]
  75. Jomova K. Raptova R. Alomar S.Y. Alwasel S.H. Nepovimova E. Kuca K. Valko M. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging. Arch. Toxicol. 2023 97 10 2499 2574 10.1007/s00204‑023‑03562‑9 37597078
    [Google Scholar]
  76. Roy S. Rauk A. Alzheimer’s disease and the ‘ABSENT’ hypothesis: Mechanism for amyloid β endothelial and neuronal toxicity. Med. Hypotheses 2005 65 1 123 137 10.1016/j.mehy.2004.08.031 15893129
    [Google Scholar]
  77. Butterfield D.A. Di Domenico F. Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim. Biophys. Acta Mol. Basis Dis. 2014 1842 9 1693 1706 10.1016/j.bbadis.2014.06.010 24949886
    [Google Scholar]
  78. Csiszar A. Tarantini S. Fülöp G.A. Kiss T. Valcarcel-Ares M.N. Galvan V. Ungvari Z. Yabluchanskiy A. Hypertension impairs neurovascular coupling and promotes microvascular injury: Role in exacerbation of Alzheimer’s disease. Geroscience 2017 39 4 359 372 10.1007/s11357‑017‑9991‑9 28853030
    [Google Scholar]
  79. A study to compare the pharmacokinetics of BR4002 and BR4002-1 in healthy volunteers. NCT04462029 2020 Available from: https://clinicaltrials.gov/
  80. Cholinergic health after menopause (CHAMP) (CHAMP). NCT04129060 2019 Available from: https://clinicaltrials.gov/
  81. A phase 1 trial to assess safety, tolerability and pharmacokinetics of ALIA-1758 in healthy participants. NCT06406348 2024 Available from: https://clinicaltrials.gov/
  82. A single dose escalation study of HHT201 in healthy subjects. NCT06373094 2024 Available from: https://clinicaltrials.gov/
  83. Dose-escalation study to assess the safety, tolerability, and pharmacokinetics from single dose of intramuscular (IM) and subcutaneous (SC) donepezil (GB-5001) injections versus donepezil oral tablet (Aricept®) in healthy male volunteers. NCT06127368 2023 Available from: https://clinicaltrials.gov/
  84. Dose-escalation study to assess the safety, tolerability, and pharmacokinetics of donepezil from single dose of GB-5001 IM depot and Aricept® oral tablets in healthy male volunteers. NCT05525780 2023 Available from: https://clinicaltrials.gov/
  85. A clinical trial to assess pharmacokinetic profiles and safety of IVL3003. NCT05345509 2024 Available from: https://clinicaltrials.gov/
  86. MK-1942/donepezil interactions in participants with Alzheimer's disease (MK-1942-005) (DDI). NCT04308304 2024 Available from: https://clinicaltrials.gov/
  87. Efficacy and safety of MK-1167 in participants with Alzheimer's disease dementia taking stable donepezil treatment (MK-1167-007). NCT06285240 2024 Available from: https://clinicaltrials.gov/
  88. Cognition platform study in participants at risk for Alzheimer's disease (AD) (MK-0000-413). NCT04730635 2024 Available from: https://clinicaltrials.gov/
  89. Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 administration in healthy adults. NCT05804279 2023 Available from: https://clinicaltrials.gov/
  90. Choline effects - Pre-symptomatic AD. NCT05880849 2025 Available from: https://clinicaltrials.gov/
  91. A multiple dose study of the safety and pharmacokinetics of NTRX-07. NCT06194552 2024 Available from: https://clinicaltrials.gov/
  92. Sequential dose-escalation study to assess the safety, tolerability and pharmacokinetics of TB006 in healthy subjects (TB006SAD). NCT04920786 2024 Available from: https://clinicaltrials.gov/
  93. A study comparing the safety, tolerability, and pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in healthy participants. NCT06511570 2024 Available from: https://clinicaltrials.gov/
  94. A study to evaluate the safety, tolerability, and blood levels of ACU193 in participants with MCI or mild AD (INTERCEPT-AD). NCT04931459 2023 Available from: https://clinicaltrials.gov/
  95. Posiphen® dose-finding, biomarker study in early Alzheimer's and Parkinson's patients. NCT04524351 2023 Available from: https://clinicaltrials.gov/
  96. Evaluating the safety, tolerability, pharmacokinetics and receptor occupancy of BMS-984923. NCT04805983 2024 Available from: https://clinicaltrials.gov/
  97. Haas L.T. Salazar S.V. Smith L.M. Zhao H.R. Cox T.O. Herber C.S. Degnan A.P. Balakrishnan A. Macor J.E. Albright C.F. Strittmatter S.M. Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer’s mouse phenotypes. Cell Rep. 2017 20 1 76 88 10.1016/j.celrep.2017.06.023 28683325
    [Google Scholar]
  98. A multiple ascending dose study in healthy volunteers and patients with Alzheimer's disease. NCT05804383 2024 Available from: https://clinicaltrials.gov/
  99. Food effect study of BMS-984923 in healthy older adult volunteers. NCT05817643 2024 Available from: https://clinicaltrials.gov/
  100. A study of SHR-1707 in healthy young adult and elderly subjects. NCT04973189 2024 Available from: https://clinicaltrials.gov/
  101. A trial of SHR-1707 infusion in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease. NCT06114745 2025 Available from: https://clinicaltrials.gov/
  102. Safety, tolerability and pharmacodynamics of SHR-1707 in Alzheimer's disease patients. NCT05681819 2025 Available from: https://clinicaltrials.gov/
  103. Brainshuttle AD: A multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7126209 following intravenous infusion in participants with prodromal or mild to moderate Alzheimer's disease. NCT04639050 2025 Available from: https://clinicaltrials.gov/
  104. Evaluating rapamycin treatment in Alzheimer's disease using positron emission tomography (ERAP). NCT06022068 2024 Available from: https://clinicaltrials.gov/
  105. A phase Ia/Ib, first-in-human (FIH) study for safety, tolerability, pharmacokinetics (PK), and clinical activity evaluation of ADEL-Y01. NCT06247345 2025 Available from: https://clinicaltrials.gov/
  106. A study to evaluate the safety and tolerability of ALN-APP in patients with EOAD. NCT05231785 2025 Available from: https://clinicaltrials.gov/
  107. Mycose administration for healing Alzheimer neuropathy (MASHIANE). NCT04663854 2020 Available from: https://clinicaltrials.gov/
  108. Cognition, age, and rapamycin effectiveness - Downregulation of the mTOR pathway (CARPE_DIEM). NCT04200911 2025 Available from: https://clinicaltrials.gov/
  109. Study to assess the pharmacokinetics of CT1812 in older healthy volunteers (COG0107). NCT05248672 2023 Available from: https://clinicaltrials.gov/
  110. Study to assess the absorption, metabolism, excretion, and mass balance of CT1812 in healthy adult male subjects (COG0108). NCT05225389 2023 Available from: https://clinicaltrials.gov/
  111. Safety and feasibility of Exablate blood-brain barrier disruption for mild cognitive impairment or mild Alzheimer's disease undergoing standard of care monoclonal antibody (mAb) therapy. NCT05469009 2025 Available from: https://clinicaltrials.gov/
  112. Multiple ascending dose safety, tolerability, PK study of AL001 in Alzheimer's disease patients & healthy adult subjects ("MAD"). NCT05363293 2025 Available from: https://clinicaltrials.gov/
  113. Evaluation of safety of Contraloid acetate in patients with mild cognitive impairment due to Alzheimer's disease. NCT04711486 2022 Available from: https://clinicaltrials.gov/
  114. A study to evaluate the pharmacokinetics and safety of BEY2153 in healthy participants. NCT04476303 2025 Available from: https://clinicaltrials.gov/
  115. Randomized I/II phase study of ALZT-OP1 combination therapy in Alzheimer's disease and normal healthy volunteers. NCT04570644 2022 Available from: https://clinicaltrials.gov/
  116. A study of LY3372993 in participants with Alzheimer's disease (AD) and healthy participants. NCT04451408 2025 Available from: https://clinicaltrials.gov/
  117. Study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TB006 in participants with Alzheimer's disease. NCT05074498 2023 Available from: https://clinicaltrials.gov/
  118. Safety, tolerability and pharmacokinetics of AD16 tablets after MAD in healthy Chinese adult subjects (MAD). NCT05806177 2023 Available from: https://clinicaltrials.gov/
  119. Peng D. Xu S. Zou T. Wang Y. Ouyang W. Zhang Y. Dong C. Li D. Guo J. Shen Q. Hu X. Zhou W. Li X. Qin Q. Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: A randomized phase 1 study. BMC Med. 2023 21 1 459 10.1186/s12916‑023‑03126‑9 37996817
    [Google Scholar]
  120. Safety and pharmacokinetics of single ascending doses and multiple ascending doses of CS6253 in healthy volunteers. NCT05965414 2025 Available from: https://clinicaltrials.gov/
  121. Kerman B.E. Noveir S.D. Xian H. Meuret C. Smadi S. Martinez A.E. Johansson J. Zetterberg H. Parks B.A. Kuklenyik Z. Johansson J.O. Yassine H.N. Strong effects of the ABCA1 agonist CS6253 on Amyloidβ42/40 ratio and lipoproteins in cynomolgus monkeys. Alzheimers Dement. 2022 18 S10 e068189 10.1002/alz.068189
    [Google Scholar]
  122. A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of anle138b in Parkinson's disease. NCT04685265 2023 Available from: https://clinicaltrials.gov/
  123. Pilot study to investigate the safety and feasibility of antiretroviral therapy for Alzheimer's disease (ART-AD). NCT04552795 2024 Available from: https://clinicaltrials.gov/
  124. Exploratory evaluation of [11C]MPC6827. NCT04575727 2025 Available from: https://clinicaltrials.gov/
  125. UAB Alzheimer's Disease Center core cohort - Tau imaging substudy (AV1451 ADC). NCT03809351 2024 Available from: https://clinicaltrials.gov/
  126. Safety, tolerability, pharmacokinetic, and pharmacodynamic study of oral ASN51 in healthy subjects and subjects with Alzheimer's disease. NCT04759365 2023 Available from: https://clinicaltrials.gov/
  127. Phase 1 study of OLX-07010 in healthy adult and elderly participants. NCT05696483 2025 Available from: https://clinicaltrials.gov/
  128. Leucettinib-21 first-in-human phase 1 in healthy volunteers and subjects with Down syndrome and Alzheimer's disease (LEUCETTA). NCT06206824 2024 Available from: https://clinicaltrials.gov/
  129. A first-in-human study to assess single doses of APNmAb005 in healthy participants. NCT05344989 2023 Available from: https://clinicaltrials.gov/
  130. Repurposing nucleoside reverse transcriptase inhibitors for treatment of AD (LINE-AD). NCT04500847 2025 Available from: https://clinicaltrials.gov/
  131. Study of safety, tolerability, pharmacodynamics and pharmacokinetics of NIO752 in early Alzheimer's disease participants. NCT05469360 2025 Available from: https://clinicaltrials.gov/
  132. A trial evaluating the effect of NIO752 on tau synthesis measured by a process known as SILK (NIO-SILK). NCT06372821 2024 Available from: https://clinicaltrials.gov/
  133. Biomarker study: Heart failure patients at risk. NCT05336175 2022 Available from: https://clinicaltrials.gov/
  134. Does BCG vaccination reduce biomarkers of Alzheimer's disease? (BCG-AD). NCT06078891 2025 Available from: https://clinicaltrials.gov/
  135. Probiotics in mild Alzheimer's disease. NCT06181513 2024 Available from: https://clinicaltrials.gov/
  136. SEMA4D blockade safety and brain metabolic activity in Alzheimer's disease (AD) (SIGNAL-AD). NCT04381468 2024 Available from: https://clinicaltrials.gov/
  137. Proof-of-concept study of new imaging diagnostic in patients with suspected Alzheimer's disease. NCT05453539 2024 Available from: https://clinicaltrials.gov/
  138. A phase 1 study of VG-3927 in healthy adults and patients with Alzheimer's disease. NCT06343636 2025 Available from: https://clinicaltrials.gov/
  139. Safety and feasibility of dasatinib and quercetin in adults at risk for Alzheimer's disease (STAMINA). NCT05422885 2025 Available from: https://clinicaltrials.gov/
  140. MAD study of NX210c (CHDR2235). NCT05827653 2024 Available from: https://clinicaltrials.gov/
  141. Greene C. Rebergue N. Fewell G. Janigro D. Godfrin Y. Campbell M. Lemarchant S. NX210c drug candidate peptide strengthens mouse and human blood-brain barriers. Fluids Barriers CNS 2024 21 1 76 10.1186/s12987‑024‑00577‑x 39334382
    [Google Scholar]
  142. Innate immunity stimulation via TLR9 in early AD. NCT05606341 2025 Available from: https://clinicaltrials.gov/
  143. Study of IGC-AD1 in subjects with dementia due to Alzheimer's disease. NCT04749563 2022 Available from: https://clinicaltrials.gov/
  144. A first time in human study of SNP318 as a treatment for neurodegenerative diseases including Alzheimer's disease. NCT05792163 2023 Available from: https://clinicaltrials.gov/
  145. Microglial colony stimulating factor-1 receptor (CSF1R) in Alzheimer's disease (MICAD). NCT04121208 2024 Available from: https://clinicaltrials.gov/
  146. Neurodegenerative Alzheimer's disease and amyotrophic lateral sclerosis (NADALS) basket trial (NADALS). NCT05189106 2024 Available from: https://clinicaltrials.gov/
  147. Safety and target engagement of Centella Asiatica in cognitive impairment. NCT05591027 2025 Available from: https://clinicaltrials.gov/
  148. Senolytic therapy to modulate progression of Alzheimer's disease (SToMP-AD). NCT04063124 2023 Available from: https://clinicaltrials.gov/
  149. ALSENLITE: Senolytics for Alzheimer's disease. NCT04785300 2025 Available from: https://clinicaltrials.gov/
  150. Lymphatic system health in Alzheimer's disease. NCT04205539 2022 Available from: https://clinicaltrials.gov/
  151. Cannabidiol solution for the treatment of behavioral symptoms in older adults with mild cognitive impairment or Alzheimer's dementia (CBD). NCT04075435 2025 Available from: https://clinicaltrials.gov/
  152. Optimization of blood levels of 25(OH)-vitamin D in African Americans. NCT04939792 2023 Available from: https://clinicaltrials.gov/
  153. Glutathione, brain metabolism and inflammation in Alzheimer's disease. NCT04740580 2025 Available from: https://clinicaltrials.gov/
  154. Recombinant human serum albumin in the treatment of AD (Alzheimer disease) exploratory clinical trials. NCT06489015 2024 Available from: https://clinicaltrials.gov/
  155. 2-hydroxybenzylamine (2-HOBA) study in early Alzheimer's patients (2-HOBA). NCT06432166 2025 Available from: https://clinicaltrials.gov/
  156. First-in-human (FIH), single ascending dose (SAD) study of fluoroethylNorMemantine (FENM). NCT05921929 2024 Available from: https://clinicaltrials.gov/
  157. A phase I study of DDN-A-0101 in healthy volunteers and elderly people. NCT06367426 2024 Available from: https://clinicaltrials.gov/
  158. To explore the therapeutic potential of Jiedu Yizhi formula for Alzheimer's disease. NCT06393413 2024 Available from: https://clinicaltrials.gov/
  159. The efficacy of traditional Chinese herbal medicine for Alzheimer's disease. NCT04249869 2020 Available from: https://clinicaltrials.gov/
  160. A phase 1 safety and tolerability study of TML-6 in healthy and elderly volunteers for Alzheimer's disease treatment. NCT06562114 2024 Available from: https://clinicaltrials.gov/
  161. Effects of nicotinamide riboside on bioenergetics and oxidative stress in mild cognitive impairment/Alzheimer's dementia. NCT04430517 2024 Available from: https://clinicaltrials.gov/
  162. Nicotinic acid for the treatment of Alzheimer's disease. NCT06582706 2025 Available from: https://clinicaltrials.gov/
  163. Sirtuin-NAD activator in Alzheimer's disease. NCT05040321 2025 Available from: https://clinicaltrials.gov/
  164. A study assessing the safety and tolerability of LY03020 in Chinese healthy subjects. NCT06556966 2024 Available from: https://clinicaltrials.gov/
  165. Safety and pharmacokinetic study of NPT 2042 soft-gelatin capsules administered orally to healthy adult subjects. NCT05503511 2023 Available from: https://clinicaltrials.gov/
  166. AC-OLE-01-VA tolerability study in healthy participants under different dosing conditions. NCT05628636 2023 Available from: https://clinicaltrials.gov/
  167. A phase 1, two-part, randomized study to evaluate the pharmacokinetics, safety, and tolerability of a liquid formulation of tricaprilin and matching placebo in healthy subjects. NCT05408780 2023 Available from: https://clinicaltrials.gov/
  168. Tricaprilin liquid formulation PK study. NCT05028114 2023 Available from: https://clinicaltrials.gov/
  169. Study to compare the pharmacokinetics of daily administration of tricaprilin on ketone body production. NCT04268953 2020 Available from: https://clinicaltrials.gov/
  170. Safety, tolerability and pharmacokinetics of CMS121, a drug candidate for Alzheimer's disease, in healthy subjects (CMS121). NCT05318040 2023 Available from: https://clinicaltrials.gov/
  171. Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease. 2019
    [Google Scholar]
  172. Psilocybin for depression in people with mild cognitive impairment or early Alzheimer's disease. NCT04123314 2024 Available from: https://clinicaltrials.gov/
  173. A phase 1 (first in human) randomized, double-blind, placebo-controlled SAD, MAD study with oral REM0046127. NCT04672135 2022 Available from: https://clinicaltrials.gov/
  174. Morató X. Pytel V. Jofresa S. Ruiz A. Boada M. Symptomatic and disease-modifying therapy pipeline for Alzheimer’s disease: Towards a personalized polypharmacology patient-centered approach. Int. J. Mol. Sci. 2022 23 16 9305 10.3390/ijms23169305 36012569
    [Google Scholar]
  175. Study to evaluate the effects of single ascending oral doses of ACD856 on safety, tolerability and pharmacokinetics. NCT05077631 2022 Available from: https://clinicaltrials.gov/
  176. Study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ACD856. NCT05077501 2022 Available from: https://clinicaltrials.gov/
  177. Study evaluating the pharmacokinetics of a single microdose of ACD856. NCT05783830 2023 Available from: https://clinicaltrials.gov/
  178. MK-8189 safety and tolerability in participants with Alzheimer's disease with or without symptoms of agitation-aggression and/or psychosis (MK-8189-017). NCT05227118 2024 Available from: https://clinicaltrials.gov/
  179. Imbimbo C. Cotta Ramusino M. Leone S. Mazzacane F. De Franco V. Gatti A. Perini G. Costa A. Emerging pharmacological approaches for psychosis and agitation in Alzheimer’s disease. CNS Drugs 2025 39 2 143 160 10.1007/s40263‑024‑01133‑9 39623197
    [Google Scholar]
  180. Study to evaluate the effects of NMRA-323511 among healthy elderly and adults with agitation associated with dementia due to Alzheimer's disease. NCT06546995 2025 Available from: https://clinicaltrials.gov/
  181. A multiple dose trial of Emraclidine in elderly participants and in participants with dementia due to Alzheimer's disease. NCT05644977 2025 Available from: https://clinicaltrials.gov/
  182. Repurposing bromocriptine for Abeta metabolism in Alzheimer's disease (REBRAnD). NCT04413344 2022 Available from: https://clinicaltrials.gov/
  183. A double-blind, placebo-controlled, dose ranging study of Xanamem® in healthy elderly volunteers (XanaMIA-DR). NCT04983368 2025 Available from: https://clinicaltrials.gov/
  184. A study to assess the adverse events and how oral ABBV-552 capsules move through the body of healthy adult Japanese and Han Chinese participants. NCT05686980 2023 Available from: https://clinicaltrials.gov/
  185. Transcranial magnetic stimulation treatment for Alzheimer's disease. NCT06538311 2025 Available from: https://clinicaltrials.gov/
  186. A study of PBFT02 in participants with FTD and mutations in the granulin precursor (GRN) or C9ORF72 genes (upliFT-D). NCT04747431 2025 Available from: https://clinicaltrials.gov/
  187. A phase 1, SAD study to evaluate the safety and tolerability of LY03017. NCT06388551 2024 Available from: https://clinicaltrials.gov/
  188. A study to evaluate the effects of itraconazole on MK-1708 in healthy participants (MK-1708-003). NCT06586606 2024 Available from: https://clinicaltrials.gov/
  189. A first-in-human study of LY3954068 in participants with early symptomatic Alzheimer's disease. NCT06297590 2025 Available from: https://clinicaltrials.gov/
  190. BnH-015B clinical trial in moderate Alzheimer's disease. NCT06535308 2025 Available from: https://clinicaltrials.gov/
  191. Lee W. Kim M. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. Medicine 2024 103 24 e38067 10.1097/MD.0000000000038067 38875437
    [Google Scholar]
  192. Yaghmaei E. Lu H. Ehwerhemuepha L. Zheng J. Danioko S. Rezaie A. Sajjadi S.A. Rakovski C. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients. Commun. Med. 2024 4 1 99 10.1038/s43856‑024‑00527‑6 38783011
    [Google Scholar]
  193. Dominantly inherited Alzheimer network trial: An opportunity to prevent dementia. A study of potential disease modifying treatments in individuals with a type of early onset Alzheimer's disease caused by a genetic mutation (DIAN-TU) (DIAN-TU). NCT05269394 2025 Available from: https://clinicaltrials.gov/
  194. A dose-ranging study to investigate efficacy of Buntanetap in mild to moderate AD. NCT05686044 2025 Available from: https://clinicaltrials.gov/
  195. Dominantly inherited Alzheimer network trial: An opportunity to prevent dementia: A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer's disease caused by a genetic mutation (DIAN-TU). NCT06424236 2025 Available from: https://clinicaltrials.gov/
  196. A study to evaluate the safety and tolerability of long-term administration of Gantenerumab in participants with Alzheimer's disease (AD). NCT04339413 2024 Available from: https://clinicaltrials.gov/
  197. A study to evaluate the safety, tolerability, and efficacy of long-term Gantenerumab administration in participants with Alzheimer's disease (AD). NCT04374253 2024 Available from: https://clinicaltrials.gov/
  198. A study to evaluate the efficacy and safety of Gantenerumab in participants at risk for or at the earliest stages of Alzheimer's disease (AD) (SKYLINE). NCT05256134 2024 Available from: https://clinicaltrials.gov/
  199. Long-term extension of phase 3 study of ALZ-801 in APOE4/4 early AD subjects (APOLLOE4-LTE). NCT06304883 2025 Available from: https://clinicaltrials.gov/
  200. An efficacy and safety study of ALZ-801 in APOE4/4 early AD subjects (APOLLOE4). NCT04770220 2025 Available from: https://clinicaltrials.gov/
  201. Multimodal biomarkers for diagnosis and prognosis in VCI (VCI). NCT04604600 2020 Available from: https://clinicaltrials.gov/
  202. A Donanemab (LY3002813) study in participants with preclinical Alzheimer's disease (TRAILBLAZER-ALZ 3). NCT05026866 2025 Available from: https://clinicaltrials.gov/
  203. A study of Donanemab (LY3002813) in participants with early Alzheimer's disease (TRAILBLAZER-ALZ 2). NCT04437511 2025 Available from: https://clinicaltrials.gov/
  204. DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease (DIAN-TU). NCT06384573 2025 Available from: https://clinicaltrials.gov/
  205. AHEAD 3-45 Study: A study to evaluate efficacy and safety of treatment with Lecanemab in participants with preclinical Alzheimer's disease and elevated amyloid and also in participants with early preclinical Alzheimer's disease and intermediate amyloid. NCT04468659 2025 Available from: https://clinicaltrials.gov/
  206. A study of Remternetug (LY3372993) in participants with Alzheimer's disease (TRAILRUNNER-ALZ 1). NCT05463731 2025 Available from: https://clinicaltrials.gov/
  207. A study of Donanemab (LY3002813) compared with Aducanumab in participants with early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ 4). NCT05108922 2024 Available from: https://clinicaltrials.gov/
  208. A study to verify the clinical benefit of Aducanumab in participants with early Alzheimer's disease (ENVISION). NCT05310071 2025 Available from: https://clinicaltrials.gov/
  209. A study to evaluate safety and tolerability of Aducanumab in participants with Alzheimer's disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. NCT04241068 2025 Available from: https://clinicaltrials.gov/
  210. PET imaging tau accumulation in FTLD and atypical Alzheimer's using PI-2620. NCT05456503 2024 Available from: https://clinicaltrials.gov/
  211. A study to evaluate KarXT as a treatment for psychosis associated with Alzheimer's disease (ADEPT-4). NCT06585787 2025 Available from: https://clinicaltrials.gov/
  212. A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer's disease (ADEPT-2). NCT06126224 2025 Available from: https://clinicaltrials.gov/
  213. Open-label extension study to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease (ADEPT-3). NCT05980949 2025 Available from: https://clinicaltrials.gov/
  214. A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer's disease (ADEPT-1). NCT05511363 2025 Available from: https://clinicaltrials.gov/
  215. BPDO-1603 intervention trial in patients with moderate-to-severe Alzheimer's disease. NCT04229927 2020 Available from: https://clinicaltrials.gov/
  216. GV1001 subcutaneous for the treatment of moderate to severe Alzheimer's disease (AD). NCT05303701 2024 Available from: https://clinicaltrials.gov/
  217. A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease. NCT05891496 2025 Available from: https://clinicaltrials.gov/
  218. A research study investigating semaglutide in people with early Alzheimer's disease (EVOKE Plus) (EVOKE Plus). NCT04777409 2025 Available from: https://clinicaltrials.gov/
  219. A research study investigating semaglutide in people with early Alzheimer's disease (EVOKE) (EVOKE). NCT04777396 2025 Available from: https://clinicaltrials.gov/
  220. Effect of hydralazine on Alzheimer's disease (EHSAN). NCT04842552 2022 Available from: https://clinicaltrials.gov/
  221. Masitinib in patients with mild to moderate Alzheimer's disease. NCT05564169 2023 Available from: https://clinicaltrials.gov/
  222. Effect of caffeine on cognition in Alzheimer's disease (CAFCA). NCT04570085 2025 Available from: https://clinicaltrials.gov/
  223. Evaluating the efficacy and safety of nilotinib BE in subjects with early Alzheimer's disease (NILEAD). NCT05143528 2021 Available from: https://clinicaltrials.gov/
  224. Simufilam 100 Mg for mild-to-moderate Alzheimer's disease (RETHINK-ALZ). NCT04994483 2024 Available from: https://clinicaltrials.gov/
  225. Open-label extension for phase 3 clinical trials of Simufilam. NCT05575076 2025 Available from: https://clinicaltrials.gov/
  226. Simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer's disease (REFOCUS-ALZ). NCT05026177 2025 Available from: https://clinicaltrials.gov/
  227. A phase 3 study of NE3107 in probable Alzheimer's disease. NCT04669028 2023 Available from: https://clinicaltrials.gov/
  228. A study of sodium Oligomannate (GV-971) in participants with mild to moderate Alzheimer's disease (GREEN MEMORY). NCT04520412 2022 Available from: https://clinicaltrials.gov/
  229. Open label study of ATH-1017 for treatment of mild to moderate Alzheimer's disease. NCT04886063 2025 Available from: https://clinicaltrials.gov/
  230. ATH-1017 for treatment of mild to moderate Alzheimer's disease (LIFT-AD). NCT04488419 2025 Available from: https://clinicaltrials.gov/
  231. Phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease (Polaris-AD). NCT05531526 2025 Available from: https://clinicaltrials.gov/
  232. Xi T. Kim F. Kim J.W. Jung J-S. Jeon E. Jo H. Nam J-S. Song D-K. Choung J.J. Target engagement and therapeutic effects of AR1001, a Phosphodiesterase‐5 inhibitor, in Alzheimer’s Disease models. Alzheimers Dement. 2024 20 S8 e095314 10.1002/alz.095314
    [Google Scholar]
  233. A phase 2 clinical study to explore the optimal dosage/administration of PM012 tablet in Alzheimer's disease (PM012-2b). NCT05811000 2023 Available from: https://clinicaltrials.gov/
  234. Piromelatine 20 mg in participants with mild dementia due to Alzheimer's disease. NCT05267535 2024 Available from: https://clinicaltrials.gov/
  235. Assessing clinical outcomes in Alzheimer's disease agitation. NCT04797715 2023 Available from: https://clinicaltrials.gov/
  236. A study to assess the efficacy and safety of AXS-05 in subjects with Alzheimer's disease agitation (ADVANCE-2). NCT05557409 2025 Available from: https://clinicaltrials.gov/
  237. A study to assess the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease agitation (ACCORD-2). NCT04947553 2025 Available from: https://clinicaltrials.gov/
  238. Nabilone for agitation blinded intervention trial (NAB-IT). NCT04516057 2025 Available from: https://clinicaltrials.gov/
  239. A phase iii multi regional clinical trial (MRCT) of tricaprilin in mild to moderately severe probable alzheimer's disease with optional open label extension. NCT04187547 2023 Available from: https://clinicaltrials.gov/
  240. Metformin in alzheimer's dementia prevention (MAP). NCT04098666 2025 Available from: https://clinicaltrials.gov/
  241. ACP-204 in adults with alzheimer's disease psychosis. NCT06159673 2025 Available from: https://clinicaltrials.gov/
  242. Masupirdine for the treatment of agitation in dementia of the alzheimer's type. NCT05397639 2025 Available from: https://clinicaltrials.gov/
  243. Assessment of the efficacy, safety, and tolerability of avp-786 for the treatment of agitation in patients with dementia of the alzheimer's type. NCT04408755 2025 Available from: https://clinicaltrials.gov/
  244. Brosch J. A Phase 3 multicenter randomized double-blind placebo-controlled study to assess the efficacy safety and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type. 2020 Available from: https://research-studies.allinforhealth.info/us/en/listing/1049/a-phase-3-multicenter-5/
  245. Phase 3 clinical trial of wujia yizhi granules in the treatment of mild-to-moderate alzheimer's dementia (syndrome of deficiency of spleen and kidney). NCT06534723 2024 Available from: https://clinicaltrials.gov/
  246. Efficacy and safety of choline alfoscerate in patient with mild to moderate alzheimer's disease (coala). NCT05383183 2024 Available from: https://clinicaltrials.gov/
  247. Evaluation of the contribution of regular cognitive exercises to treatment in patients with alzheimer's disease. NCT03954613 2022 Available from: https://clinicaltrials.gov/
  248. Comparison of therapeutic strategies with cholinesterase inhibitors (sos trial). NCT03454646 2023 Available from: https://clinicaltrials.gov/
  249. Monitoring anti-dementia drugs by serum levels (monanti). NCT04117178 2025 Available from: https://clinicaltrials.gov/
  250. Efficacy and safety of memantine and sodium oligomannate in patients with moderate to severe Alzheimer's disease. NCT05430867 2022 Available from: https://clinicaltrials.gov/
  251. Long-term efficacy and safety study of GV-971. NCT05181475 2024 Available from: https://clinicaltrials.gov/
  252. A clinical study to evaluate the long-term safety of sodium oligomannate capsules (GV-971). NCT05058040 2025 Available from: https://clinicaltrials.gov/
  253. An efficacy and safety study of sodium oligomannate (GV-971) for the treatment of Alzheimer's disease. NCT05908695 2023 Available from: https://clinicaltrials.gov/
  254. Improvement effect of lacosamide and levetiracetam on cognitive in Alzheimer's disease patients with epilepsy. NCT05969054 2023 Available from: https://clinicaltrials.gov/
  255. Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease (DARIDOR-ALZ). NCT05924425 2024 Available from: https://clinicaltrials.gov/
  256. Lemborexant for insomnia in a patient with dementia: An N-of-1 trial. NCT06093126 2025 Available from: https://clinicaltrials.gov/
  257. Aβ dynamics in LLMD. NCT05004987 2025 Available from: https://clinicaltrials.gov/
  258. Spironolactone safety in african americans with mild cognitive impairment and early dementia (stand). NCT04522739 2024 Available from: https://clinicaltrials.gov/
  259. Bateman R.J. Smith J. Donohue M.C. Delmar P. Abbas R. Salloway S. Wojtowicz J. Blennow K. Bittner T. Black S.E. Klein G. Boada M. Grimmer T. Tamaoka A. Perry R.J. Turner R.S. Watson D. Woodward M. Thanasopoulou A. Lane C. Baudler M. Fox N.C. Cummings J.L. Fontoura P. Doody R.S. Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N. Engl. J. Med. 2023 389 20 1862 1876 10.1056/NEJMoa2304430 37966285
    [Google Scholar]
  260. Sperling R.A. Donohue M.C. Raman R. Rafii M.S. Johnson K. Masters C.L. van Dyck C.H. Iwatsubo T. Marshall G.A. Yaari R. Mancini M. Holdridge K.C. Case M. Sims J.R. Aisen P.S. Trial of solanezumab in preclinical Alzheimer’s disease. N. Engl. J. Med. 2023 389 12 1096 1107 10.1056/NEJMoa2305032 37458272
    [Google Scholar]
  261. Hurdle J. Genentech provides update on Alzheimer’s prevention initiative study evaluating crenezumab in autosomal dominant alzheimer’s disease. 2022 Available from: https://www.gene.com/media/press-releases/14957/2022-06-15/genentech-provides-update-on-alzheimers-
  262. Wessels A.M. Tariot P.N. Zimmer J.A. Selzler K.J. Bragg S.M. Andersen S.W. Landry J. Krull J.H. Downing A.M. Willis B.A. Shcherbinin S. Mullen J. Barker P. Schumi J. Shering C. Matthews B.R. Stern R.A. Vellas B. Cohen S. MacSweeney E. Boada M. Sims J.R. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease. JAMA Neurol. 2020 77 2 199 209 10.1001/jamaneurol.2019.3988 31764959
    [Google Scholar]
  263. Monteiro C. Toth B. Brunstein F. Bobbala A. Datta S. Ceniceros R. Sanabria Bohorquez S.M. Anania V.G. Wildsmith K.R. Schauer S.P. Lee J. Dolton M.J. Ramakrishnan V. Abramzon D. Teng E. Aggarwal P. Agronin M. Ala T. Arnold J. Arnold T. Toledo M.B. Gonzalez R.B. Rovira M.B. Bond W. Brody M. Ceccaldi M. Czarnecki M. Del Olmo Rodriguez A. Dobryniewski J. Dubois B. Edwards K. Forchetti C. Goldstein M. Goodman I. Cezara R.H. Ilkowski J. Justiz W. KrolakSalmon P. Krupinski J. Pascual L.L. Levy R. Bisa A.L. Losk S. MaldonadoRobles O. Marshall G. Martinez W. McAllister P. McElveen W.A. McGinnis S. Mickielewicz A. Mollion H. Murphy C. Nair A. Nair M. Omidvar O. Oskooilar N. Patel P. Porsteinsson A. Ratajczak M. Riddle M. Rosenbloom M. Russell D. Salloway S. Del Valle Diaz R.S. Sha S. Shah R. Sharma S. Smith W. Sood A. Stein L. Stoukides J. Thein S. Watson D. Weisman D. Zboch M. Zielinski T. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet. Neurology 2023 101 14 e1391 e1401 10.1212/WNL.0000000000207663 37643887
    [Google Scholar]
  264. Götz J. Richter-Stretton G. Cruz E. Therapeutic ultrasound as a treatment modality for physiological and pathological ageing including alzheimer’s disease. Pharmaceutics 2021 13 7 1002 10.3390/pharmaceutics13071002 34371696
    [Google Scholar]
  265. Qiu Y. Messer K. Jacobs D.M. Salmon D.P. Kaplita S. Wellington C.L. Stukas S.K. Askew B. Brewer J.B. Brody M. Donahue L. Drake J.D. Grossman K. Hendrix S.B. Jicha G.A. Leger G.C. Porsteinsson A.P. Shadyab A.H. Taylor C. Thomas R.G. van Dyck C.H. Zhang J. Coric V. Qureshi I. Feldman H.H. Prognostic value of plasma biomarkers in a clinical trial of mild‐to‐moderate Alzheimer’s disease. Alzheimers Dement. 2023 19 S15 e076047 10.1002/alz.076047
    [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273387383250924031644
Loading
Hypothesis-Driven Insights and Clinical Trial Updates in Alzheimer’s Disease Pathogenesis
Bentham Science Publishers ; https://doi.org/10.2174/0118715273387383250924031644
/content/journals/cnsnddt/10.2174/0118715273387383250924031644
/content/journals/cnsnddt/10.2174/0118715273387383250924031644
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: tau protein ; amyloid-beta ; Alzheimer's disease ; dementia ; acetylcholinesterase inhibitors ; neuroinflammation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test